ID   CTB-1
AC   CVCL_1149
SY   CTB1
DR   CLO; CLO_0050077
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03472128
DR   cancercelllines; CVCL_1149
DR   Cell_Model_Passport; SIDM00283
DR   ChEMBL-Cells; CHEMBL3308188
DR   ChEMBL-Targets; CHEMBL2366344
DR   Cosmic; 949088
DR   Cosmic; 2297019
DR   Cosmic; 2437311
DR   Cosmic-CLP; 949088
DR   DepMap; ACH-002221
DR   EGA; EGAS00001000978
DR   GDSC; 949088
DR   GEO; GSM119489
DR   GEO; GSM1669711
DR   IARC_TP53; 27552
DR   LINCS_LDP; LCL-1118
DR   PharmacoDB; CTB1_267_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1149
DR   PubChem_Cell_line; CVCL_1149
DR   RCB; RCB1316
DR   Wikidata; Q54814731
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=16960149;
RX   PubMed=20164919;
RX   PubMed=21533490;
RX   PubMed=26727417;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 36 hours (PubMed=21533490).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.Ser462fs (c.1386delT); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0.23%; East Asian, North=25.3%; East Asian, South=74.47%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Derived from site: Metastatic; Pericardial effusion; UBERON=UBERON_0002409.
ST   Source(s): Cosmic-CLP; RCB
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8,9
ST   D16S539: 11,12
ST   D5S818: 11,13
ST   D7S820: 11
ST   TH01: 9
ST   TPOX: 8,11
ST   vWA: 16,17
DI   NCIt; C8851; Diffuse large B-cell lymphoma
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   70Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 36
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=16960149; DOI=10.1182/blood-2006-06-026500;
RA   Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R.,
RA   Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marin M.,
RA   Rosenwald A., Sugimoto K.-j., Wheat L.M., Karran E.L., Garcia J.F.,
RA   Sanchez-Verde L., Prosper F., Staudt L.M., Pinkel D., Dyer M.J.S.,
RA   Martinez-Climent J.A.;
RT   "Homozygous deletions localize novel tumor suppressor genes in B-cell
RT   lymphomas.";
RL   Blood 109:271-280(2007).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=21533490; DOI=10.3892/ijo.10.6.1103;
RA   Uchida Y., Miyazawa K., Yaguchi M., Gotoh A., Iwase O., Ohyashiki K.,
RA   Toyama K.;
RT   "Establishment of a novel B-lymphoma cell line, CTB-1, with strong Pas
RT   antigen expression having chromosomal translocation (14;22).";
RL   Int. J. Oncol. 10:1103-1107(1997).
//
RX   PubMed=26727417; DOI=10.3109/10428194.2015.1108414;
RA   Drexler H.G., Eberth S., Nagel S., MacLeod R.A.F.;
RT   "Malignant hematopoietic cell lines: in vitro models for double-hit
RT   B-cell lymphomas.";
RL   Leuk. Lymphoma 57:1015-1020(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//